Pasithea Therapeutics Narrows Q1 Net Loss to $2.87M, EPS Improves to $(0.12)
KTTA has more than doubled off its 52-week low of $0.281.
Summary
Pasithea Therapeutics Corp. reported its first-quarter 2026 financial results, showing a net loss of $(2.87) million, a significant improvement from the $(3.56) million loss in Q1 2025. Diluted loss per share also improved to $(0.12) from $(1.61) year-over-year. This positive financial trend, coupled with ongoing Phase 1 dose-escalation trials for PAS-004 and IND clearance for registrational programs, provides a crucial update on the company's progress. The company also highlighted sufficient cash for at least 12 months, with future funding potentially relying on equity, debt, or partnerships. Traders will monitor continued clinical advancements and future financing strategies.
At the time of this announcement, KTTA was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.5M. The 52-week trading range was $0.28 to $2.06. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.